-
Arrowhead's Big Sell-Off Presents Buying Opportunity, According to HC Wainwright
Tuesday, July 6, 2021 - 5:36pm | 276Read More...The sell-off on shares of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) tied to the ARO-EnAC phase 1/2 study halt is overdone, leading H.C. Wainwright & Co. to reiterate its Buy rating. The Arrowhead Analyst: H.C. Wainwright & Co. analyst Patrick Trucchio reiterated the firm...
